Cargando…

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

BACKGROUND: Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19. METHODS:...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362594/ https://www.ncbi.nlm.nih.gov/pubmed/34351721 http://dx.doi.org/10.1056/NEJMoa2105911

Ejemplares similares

Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19
por: Stone, Gregg W., et al.
Publicado: (2023)

EVALUATION OF THERAPEUTIC VS PROPHYLACTIC ANTICOAGULATION IN NONCRITICALLY ILL PATIENTS HOSPITALIZED WITH COVID-19 PNEUMONIA
por: GHOSH, KULDEEP, et al.
Publicado: (2022)

Anticoagulation is the answer in treating noncritical COVID-19 patients
por: Kabir, Azad A.
Publicado: (2021)

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
Publicado: (2021)

Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients
por: Kovačević, Tijana, et al.
Publicado: (2016)

CRITICALLY ILL COVID-19 PATIENTS AND THERAPEUTIC ANTICOAGULATION WITH HEPARIN
por: Vu, Michael, et al.
Publicado: (2022)

Efficacy and safety of therapeutic vs. prophylactic bemiparin in noncritically ill patients with COVID-19 pneumonia
por: Varona, Jose F, et al.
Publicado: (2022)

Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
por: Poletto, Francesco, et al.
Publicado: (2022)

Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients
por: Mendez, Carlos E., et al.
Publicado: (2014)

A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19
por: Shuto, Hisayuki, et al.
Publicado: (2020)

Effect of therapeutic-dose heparin on severe acute kidney injury and death in noncritically ill patients hospitalized for COVID-19: a prespecified secondary analysis of the ACTIV4a and ATTACC randomized trial
por: Smilowitz, Nathaniel R., et al.
Publicado: (2023)

Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients
por: Gonzalez-Gonzalez, Jose Gerardo, et al.
Publicado: (2013)

Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection
por: McGlynn, Fergal, et al.
Publicado: (2020)

Telehealth for Noncritical Patients With Chronic Diseases During the COVID-19 Pandemic
por: Liu, Na, et al.
Publicado: (2020)

Increased Glycemic Variability Is Independently Associated With Length of Stay and Mortality in Noncritically Ill Hospitalized Patients
por: Mendez, Carlos E., et al.
Publicado: (2013)

Patient characteristics and admitting vital signs associated with coronavirus disease 2019 (COVID-19)–related mortality among patients admitted with noncritical illness
por: Sands, Kenneth E., et al.
Publicado: (2020)

Regional Anticoagulation with Citrate is Superior to Systemic Anticoagulation with Heparin in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration
por: Park, Joon-Sung, et al.
Publicado: (2011)

Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial
por: Zuily, Stéphane, et al.
Publicado: (2023)

Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards
por: Gupta, Tina, et al.
Publicado: (2017)

Continuation of therapeutic dose heparin for critically ill patients with COVID-19
por: Bradbury, Charlotte A., et al.
Publicado: (2023)

Follow-up of adults with noncritical COVID-19 two months after symptom onset
por: Carvalho-Schneider, Claudia, et al.
Publicado: (2021)

Role of the Bronchoalveolar Lavage in Noncritically Ill Patients during the SARS-CoV-2 Epidemic
por: Taton, Olivier, et al.
Publicado: (2020)

Optimal systolic blood pressure in noncritically ill patients with acute kidney injury: A retrospective cohort study
por: Baek, Seon Ha, et al.
Publicado: (2019)

Hypothalamic-Pituitary-Adrenal Axis Activity in SARS-CoV-2 Infected Noncritically Ill Hospitalized Patients
por: Banu, Hurjahan, et al.
Publicado: (2023)

Non-anticoagulant heparin derivatives for COVID-19 treatment
por: Cao, Min, et al.
Publicado: (2023)

Bivalirudin or heparin: which anticoagulation strategy for critically ill cardiac surgery patients?
por: Pappalardo, F, et al.
Publicado: (2014)

Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU
por: ÇALIK BAŞARAN, Nursel, et al.
Publicado: (2021)

Nutritional profile and outcomes of noncritical hospitalized patients with COVID-19 in a large tertiary hospital in southern Brazil
por: Nunes, Emeline Caldana, et al.
Publicado: (2022)

Key patient demographics shape innate immune topography in noncritical hypoxic COVID-19 pneumonia
por: Billi, Allison C., et al.
Publicado: (2023)

Feasibility and Usability of Patch-based Continuous Cardiac Rhythm Monitoring in Comparison with Traditional Telemetry in Noncritically Ill Hospitalized Patients
por: Amuthan, Ram, et al.
Publicado: (2019)

Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin
por: Ting, Clara, et al.
Publicado: (2018)

Appropriateness of proton pump inhibitors use in noncritically ill hospitalized children in a tertiary hospital in Saudi Arabia
por: Alosaily, Yousif A., et al.
Publicado: (2023)

Measuring the anticoagulant effect of low molecular weight heparins in the critically ill
por: Crowther, Mark, et al.
Publicado: (2006)

COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No
por: Jimenez, David, et al.
Publicado: (2022)

Dangers of Noncritical Use of Historical Plague Data
por: Roosen, Joris, et al.
Publicado: (2018)

Emergence of power laws in noncritical neuronal systems
por: Faqeeh, Ali, et al.
Publicado: (2019)

Outcome in noncritically ill patients with acute kidney injury requiring dialysis: Effects of differing medical staffs and organizations
por: Fagugli, Riccardo Maria, et al.
Publicado: (2016)

Management of Glucose Control in Noncritically Ill, Hospitalized Patients Receiving Parenteral and/or Enteral Nutrition: A Systematic Review
por: Laesser, Céline Isabelle, et al.
Publicado: (2019)

Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
por: Buijsers, Baranca, et al.
Publicado: (2020)

Heparin anticoagulation versus regional citrate anticoagulation for membrane therapeutic plasma exchange in patients with increased bleeding risk
por: Jiao, Jing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ni8p1gi00unp6el949svbuglj6